Genome-wide CRISPR screening reveals novel therapeutic targets in RIT1-driven lung cancer.

In recent work, we performed CRISPR/Cas9 screening in RIT1 (Ras-like in all tissues)- mutant cancer cells. We found that RIT1 -mutant cells are vulnerable to loss of mitotic regulators, and mutant RIT1 synergizes with YAP1 (yes-associated protein 1) in oncogenesis. These findings can be leveraged to identify targeted therapies for RIT1 -mutant cancer.